Juan Ignacio Vargas

749 total citations · 1 hit paper
11 papers, 547 citations indexed

About

Juan Ignacio Vargas is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, Juan Ignacio Vargas has authored 11 papers receiving a total of 547 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Rheumatology, 5 papers in Immunology and 4 papers in Hematology. Recurrent topics in Juan Ignacio Vargas's work include Rheumatoid Arthritis Research and Therapies (9 papers), Biosimilars and Bioanalytical Methods (4 papers) and Autoimmune and Inflammatory Disorders Research (4 papers). Juan Ignacio Vargas is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (9 papers), Biosimilars and Bioanalytical Methods (4 papers) and Autoimmune and Inflammatory Disorders Research (4 papers). Juan Ignacio Vargas collaborates with scholars based in United States, Japan and Austria. Juan Ignacio Vargas's co-authors include Déborah Bauer, Eun Bong Lee, Rahul Patel, Janet van Adelsberg, Neil M.H. Graham, Alan Friedman, Erin Mangan, Hubert van Hoogstraten, Yong Lin and Gerd R Burmester and has published in prestigious journals such as The Lancet, Annals of the Rheumatic Diseases and Arthritis Research & Therapy.

In The Last Decade

Juan Ignacio Vargas

10 papers receiving 529 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study

2019 260 citations Josef S Smolen, Aileen L. Pangan et al. The Lancet profile →

Peers

Countries citing papers authored by Juan Ignacio Vargas

Since Specialization

Citations

This map shows the geographic impact of Juan Ignacio Vargas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Juan Ignacio Vargas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Juan Ignacio Vargas more than expected).

Fields of papers citing papers by Juan Ignacio Vargas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Juan Ignacio Vargas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Juan Ignacio Vargas. The network helps show where Juan Ignacio Vargas may publish in the future.

Co-authorship network of co-authors of Juan Ignacio Vargas

This figure shows the co-authorship network connecting the top 25 collaborators of Juan Ignacio Vargas. A scholar is included among the top collaborators of Juan Ignacio Vargas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Juan Ignacio Vargas. Juan Ignacio Vargas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study 2025 ·RMD Open ·Josef S Smolen, Paul Emery, William F. C. Rigby, Yoshiya Tanaka, Juan Ignacio Vargas, (unknown), Koji Kato, (unknown), Nasser Khan, Charles D. Phillips, Sebastian Meerwein, Stanley Cohen	0
2	Association between Drug Use and Perception of Mental Health in Women Diagnosed with Fibromyalgia: An Observational Study 2024 ·Biomedicines ·(unknown), (unknown), Ángel Roco-Videla, Juan Ignacio Vargas, (unknown), (unknown), (unknown), Nelson Maureira-Carsalade, Sergio Flores	2
3	POS0847 UPADACITINIB AS MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO METHOTREXATE: RESULTS AT 260 WEEKS FROM THE SELECT-MONOTHERAPY STUDY 2023 ·Josef S Smolen, Paul Emery, William F. C. Rigby, Yoshiya Tanaka, Juan Ignacio Vargas, Nemanja Damjanov, (unknown), Keisuke Kato, (unknown), (unknown), Heidi S. Camp, Stanley Cohen	1
4	Safety of upadacitinib in Latin American patients with rheumatoid arthritis: an integrated safety analysis of the SELECT phase 3 clinical program 2023 ·Clinical Rheumatology ·Adriana María Kakehasi, S. Radominski, (unknown), (unknown), Conrado García-García, Maysa Silva Arruda, (unknown), John Liu, Meihua Qiao, (unknown), Juan Ignacio Vargas	2
5	Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study 2022 ·RMD Open ·Kevin Winthrop, Juan Ignacio Vargas, Edit Drescher, (unknown), Alan Friedman, Barbara A. Hendrickson, Yihan Li, (unknown), Alan Kivitz	10
6	POS0508 EVALUATION OF RESPONSE TO PNEUMOCOCCAL VACCINATION IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING UPADACITINIB: RESULTS FROM A PHASE 2 OPEN-LABEL EXTENSION STUDY 2021 ·Annals of the Rheumatic Diseases ·Kevin Winthrop, Juan Ignacio Vargas, Edit Drescher, Conrado García-García, A. Friedman, Jeffrey Enejosa, (unknown), (unknown), (unknown), Alan Kivitz	1
7	THU0213 UPADACITINIB AS MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO METHOTREXATE: RESULTS AT 84 WEEKS FROM THE SELECT-MONOTHERAPY STUDY 2020 ·Annals of the Rheumatic Diseases ·Josef S Smolen, Paul Emery, William F. C. Rigby, Yoshiya Tanaka, Juan Ignacio Vargas, Nemanja Damjanov, (unknown), (unknown), (unknown), (unknown), Stanley Cohen	3
8	Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study breakdown → 2019 ·The Lancet ·Josef S Smolen, Aileen L. Pangan, Paul Emery, William F. C. Rigby, Yoshiya Tanaka, Juan Ignacio Vargas, Ying Zhang, Nemanja Damjanov, Alan Friedman, Mohamed I. A. Othman, Heidi S. Camp, Stanley Cohen	260
9	THU0191 UPADACITINIB AS MONOTHERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS AT 48 WEEKS FROM THE SELECT-MONOTHERAPY STUDY 2019 ·Annals of the Rheumatic Diseases ·Josef S Smolen, Paul Emery, William F. C. Rigby, Yoshiya Tanaka, Juan Ignacio Vargas, Nemanja Damjanov, (unknown), Yunxia Sui, Jeffrey Enejosa, Aileen L. Pangan, Heidi S. Camp, Stanley Cohen	2
10	FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension 2019 ·Arthritis Research & Therapy ·Mark C. Genovese, (unknown), Maria Greenwald, W. Porawska, (unknown), Eva Dokoupilová, Juan Ignacio Vargas, Mykola Stanislavchuk, (unknown), Elena Baranova, (unknown), Rieke Alten	39
11	Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial 2016 ·Annals of the Rheumatic Diseases ·Gerd R Burmester, Yong Lin, Rahul Patel, Janet van Adelsberg, Erin Mangan, Neil M.H. Graham, Hubert van Hoogstraten, Déborah Bauer, Juan Ignacio Vargas, Eun Bong Lee	227

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact